Josephine Therkildsen

Josephine Therkildsen

Auto-generated profile, based on publicly available information

Josephine Therkildsen

Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Radiology
Verified
Journal Article
Closed access
JTJosephine Therkildsen
Josephine Therkildsen
LNLouise Nissen
Louise Nissen
HJHanne Skou Joergensen
Hanne Skou Joergensen
JTJesper Thygesen
Jesper Thygesen
PIPer Ivarsen
Per Ivarsen
SWSimon Winther
Simon Winther
Cardiac CT can be used to evaluate fracture rate by assessing the bone mineral density of thoracic vertebrae. Background Osteoporosis is a prevalent, under-diagnosed, and treatable disease associated with increased fracture risk. Bone mineral density (BMD) derived from cardiac CT may be used to determine f...

1 July 2018 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
JTJosephine Therkildsen
Josephine Therkildsen
JTJesper Thygesen
Jesper Thygesen
SWSimon Winther
Simon Winther
MSMy Svensson
My Svensson
EHEllen-Margrethe Hauge
Ellen-Margrethe Hauge
HJHanne Skou Joergensen
Hanne Skou Joergensen

1 January 2020 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
JTJosephine Therkildsen
Josephine Therkildsen
SWSimon Winther
Simon Winther
LNLouise Nissen
Louise Nissen
HJHanne Skou Joergensen
Hanne Skou Joergensen
JTJesper Thygesen
Jesper Thygesen
MBMorten Böttcher
Morten Böttcher

1 June 2020 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
ATAndreas Bugge Tinggaard
Andreas Bugge Tinggaard
ATAnnette de Thurah
Annette de Thurah
IAIna Trolle Andersen
Ina Trolle Andersen
ARAnders Hammerich Riis
Anders Hammerich Riis
JTJosephine Therkildsen
Josephine Therkildsen
MBMorten Bøttcher
Morten Bøttcher
Purpose: To examine the occurrence and severity of coronary artery disease (CAD) in patients with rheumatoid arthritis (RA) compared to non-RA patients in a population referred for coronary computed tomography angiography (CTA) due to chest pain. Patients and Methods: In this cross-sectional study, 46,210 patients from a national CTA database were included. Patients with RA were stratified on serology, treatment with conventional synthetic or biological disease-modifying antirheumatic drugs (DMARDs), and the need for relapse or flare treatment with intraarticular or -muscular glucocorticoid injections (GCIs). Primary outcomes were coronary artery calcium score (CACS) > 0 and CACS ≥ 400, and secondary outcome was obstructive CAD. Associations between RA and outcomes were examined using logistic regression and results were adjusted for age, sex, cardiovascular risk factors and comorbidities. Results: A total of 395 (0.9%) RA patients were identified. In overall RA, crude odds ratio (OR) for having CACS > 0 was 1.48 (1.21– 1.82) and 1.52 (1.15– 2.01) for CACS ≥ 400, whereas adjusted ORs were 1.08 (0.86– 1.36) and 1.21 (0.89– 1.65), respectively. Seropositive RA patients had adjusted OR of 1.16 (0.89– 1.50) for CACS > 0 and 1.37 (0.98– 1.90) for CACS ≥ 400. Patients who had received ≥ 1 GCI in the period of 3 years prior to the CTA had an adjusted OR of 1.37 (0.94– 2.00) for having CACS > 0 and 1.46 (0.92– 2.31) for CACS ≥ 400. Conclusion: This is the first large-scale, CTA-based study examining the occurrence and severity of CAD in RA patients with symptoms suggestive of cardiovascular disease. A higher prevalence of coronary artery calcification was found in RA patients. After adjusting for age, sex, cardiovascular risk factors and comorbidities, the tendency was less pronounced. We found a trend for increased coronary calcification in RA patients being seropositive or needing treatment with GCI for a relapse or flare.

1 January 2021 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
JTJosephine Therkildsen
Josephine Therkildsen
SWSimon Winther
Simon Winther
LNLouise Nissen
Louise Nissen
HJHanne Skou Joergensen
Hanne Skou Joergensen
JTJesper Thygesen
Jesper Thygesen
MBMorten Böttcher
Morten Böttcher

15 May 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
JTJosephine Therkildsen
Josephine Therkildsen
RKRasmus Klose-Jensen
Rasmus Klose-Jensen
MHMathias Hänel
Mathias Hänel
BLBente L Langdahl
Bente L Langdahl
JTJesper Thygesen
Jesper Thygesen
EHEllen-Margrethe Hauge
Ellen-Margrethe Hauge
Objectives: To investigate the diagnostic accuracy of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess erosive progression during 1 year compared with conventional radiography (CR) in rheumatoid arthritis (RA). Methods: This prospective study included 359 patients with RA (disease duration ≥5 years) between March 2018 and October 2020. HR-pQCT and CR were obtained at inclusion and after 1 year. Erosive assessment was performed at two metacarpophalangeal joints of the dominant hand using HR-pQCT, and progression was defined as an increase in erosion number ≥1 or an increase in erosive volume > least significant change. CR of hands, wrists and feet was evaluated using Sharp/van der Heijde scores and erosive progression was defined as a 1.1-point increase in erosion score according to the smallest detectable change. Results: In paired analyses (n = 310), erosive progression was identified in 30 patients using CR and in 40 patients using HR-pQCT. In the 40 patients with erosive progression on HR-pQCT, progression was not identified by CR in 33 patients. Adding HR-pQCT to CR doubled the proportion of patients identified with progression from 30 (10%) to 63 (20%) patients. Using CR as the reference, the sensitivity of HR-pQCT for identifying erosive progression was 23.3% (95% CI: 9.9, 42.3%) and the specificity was 88.2% (95% CI: 83.8, 91.7%). Conclusion: A substantial proportion of patients with erosive progression are overlooked using CR only to monitor erosive progression. Adding high-resolution peripheral CT to CR doubles the proportion of patients who may benefit from individualized therapy targeting erosive progression in RA.